These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18486728)

  • 21. Blocking breast cancer relapses.
    Johns Hopkins Med Lett Health After 50; 2006 Feb; 17(12):1-2. PubMed ID: 17115471
    [No Abstract]   [Full Text] [Related]  

  • 22. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.
    Bedard PL; Piccart-Gebhart MJ
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab trials steal show at ASCO meeting.
    Tuma RS
    J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
    [No Abstract]   [Full Text] [Related]  

  • 25. Complete genome sequencing and network modeling to overcome trastuzumab resistance.
    Roukos DH
    Pharmacogenomics; 2010 Aug; 11(8):1039-43. PubMed ID: 20704462
    [No Abstract]   [Full Text] [Related]  

  • 26. Kinetic concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):11-20. PubMed ID: 10190780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
    Araki K; Pegram M
    Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
    [No Abstract]   [Full Text] [Related]  

  • 28. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy.
    Fox KF
    Br J Cancer; 2006 Nov; 95(10):1454. PubMed ID: 17060943
    [No Abstract]   [Full Text] [Related]  

  • 31. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 32. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer.
    Yamashita J; Akizuki M; Jotsuka T; Harao M; Nakano S
    Breast J; 2006; 12(3):288. PubMed ID: 16684339
    [No Abstract]   [Full Text] [Related]  

  • 33. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 34. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 35. Response of metastatic breast cancer to trastuzumab?
    Barnes DM; Miles DW
    Lancet; 2000 Jan; 355(9199):160-1. PubMed ID: 10675110
    [No Abstract]   [Full Text] [Related]  

  • 36. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.
    Olver IN
    Future Oncol; 2008 Feb; 4(1):125-31. PubMed ID: 18241007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying responders to trastuzumab therapy in breast cancer.
    Brügmann A; Sorensen BS
    Future Oncol; 2011 Jun; 7(6):767-73. PubMed ID: 21675839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
    Yardley DA; Daniel D; Stipanov M; Drosick DR; Mainwaring M; Peyton J; Shastry M; Hainsworth JD
    Cancer Invest; 2010 Oct; 28(8):865-71. PubMed ID: 20690802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.